Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic mutations and inhibitors of p300 and CBP.

Biochimica et biophysica acta. Reviews on cancer - 1 Sept 2026

Robaszkiewicz Agnieszka, Cole Philip A

Abstract excerpt

The p300 and CBP highly homologous acetyltransferases, are linked to malignant transformation and cancer progression. The longstanding attempts to find small molecules to block these enzymes in cancer have led to the identification of two inhibitor classes that target the acetyltransferase catalytic domain (HAT) or acetylated protein recognizing bromodomain (BRD), and related pharmacological agents such as dual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to CREB-Binding Protein
Share to E1A-Associated p300 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to CREBBP gene

Share to Mutation

Share to Neoplasms

Share to p300-CBP Transcription Factors

Source

Identifiers

PMID: 42061730
DOI: 10.1016/j.bbcan.2026.189599

Genes

CREBBP
EP300

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic mutations and inhibitors of p300 and CBP.PMID 42061730Read ↗

Dysregulation of the p300/CBP histone acetyltransferases in human cancer.Semantic proximity Read ↗

Characteristics of anticancer activity of CBP/p300 inhibitors – Features of their classes, intracellular targets and future perspectives of their application in cancer treatmentSemantic proximity Read ↗

Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer.Semantic proximity Read ↗

Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function.Semantic proximity Read ↗

Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.Semantic proximity Read ↗

Inhibition of histone acetyltranserase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a novel gain of functionSemantic proximity Read ↗

Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphomaSemantic proximity Read ↗

Inactivating mutations of acetyltransferase genes in B-cell lymphoma.Semantic proximity Read ↗

CBP/p300 acetyltransferase activity in hematologic malignancies.Semantic proximity Read ↗

Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular CarcinomaSemantic proximity Read ↗

Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 ProteinsSemantic proximity Read ↗

Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and DogsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.